DJO Incorporated (DJO) Receives FDA Approval for Supplement to Company's Existing Pre-Market Approval
More News related to DJO
- Standard & Poor's Changes to U.S. Indices
- DJO Incorporated (DJO) Misses Q3 Views
- DJO Incorporated (DJO) Receives FDA Approval for Supplement to Company's Existing Pre-Market Approval
- DJO Incorporated (DJO) Receives Accreditation Status by Accreditation Commission for Health Care
- Blackstone (BX) Gets Antitrust OK For DJO Inc (DJO) Buyout - DJ
More News related to FDA
- Gold Higher On Reports India Could Buy the Rest of the IMF's Hoard (GLD)
- Vietnam Devalues Currency, Hikes Rates
- Deere & Company (DE) Posts Q4 EPS of $0.20, Handily Tops Estimates; Guides FY10 Earnings
- Tiffany & Co. (TIF) Posts Q3 EPS of $0.33 Ex-Items, Beats by 9c; Guides EPS Higher
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
DJO Incorporated (NYSE: DJO) has received FDA approval for a supplement to the Company's existing Pre-Market Approval (PMA). The PMA supplement covers several new product features that are built into the control modules for its Combined Magnetic Field (CMF) OL1000 and SpinaLogic® bone growth stimulation product lines. The new product features enhance patients' ease of use.
The CMF OL1000 and SpinaLogic® devices are the only bone growth stimulation devices utilizing the unique and patented CMF technology. CMF is the only waveform clinically proven to stimulate bone growth from a simple 30 minute per day treatment with FDA-indicated use in both long bone and primary lumbar Spine applications.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
